

Open clinical trials CTU

Cardiology			
Short title	Complete title	Key Inclusions	Contact
SCAD Registry	Spontaneous Coronary Artery Dissection Registry	<ul style="list-style-type: none"> Confirmed by coronary angiography a spontaneous coronary artery dissection 	PI: Matthias Meyer matthias.meyer@ksgr.ch CRC: Gabriela Manetsch gabriela.manetsch@ksgr.ch

Open clinical trials CTU

Geriatrics			
Short title	Complete title	Key Inclusions	Contact
STREAM	Discontinuing Statins in Multimorbid Older Adults without Cardiovascular Disease (STREAM) – a randomized non-inferiority clinical trial	<ul style="list-style-type: none"> • ≥70 years of age • Multimorbid with ≥2 coexistent chronic conditions, besides dyslipidemia treated by statins • Taking a statin for ≥80% of the time during the year before baseline 	PI: Martina Heim martina.heim@ksgr.ch CRC: Cornelia Fluri cornelia.fluri@ksgr.ch

Open clinical trials CTU

Gynecological			
Short title	Complete title	Key Inclusions	Contact
IPSIS	Implementing preeclampsia screening in Switzerland Study	<ul style="list-style-type: none"> Pregnant woman with a regular follow-up of their pregnancies from the first trimester who consent to participate in this trial 	PI: Carolin Blume carolin.blume@ksgr.ch CRC: Romina Bottoni romina.bottoni@ksgr.ch
ODIES	Surgery for deep infiltrating endometriosis, symptoms and outcomes	<ul style="list-style-type: none"> Indication for surgical therapy of deep infiltrating and pelvic endometriosis based on clinical and reproductive-medical criteria 	PI: Peter Fehr peter.fehr@ksgr.ch CRC: Romina Bottoni romina.bottoni@ksgr.ch

Open clinical trials CTU

Internal medicine			
Short title	Complete title	Key Inclusions	Contact
Amyloidosis	Registry Amyloidose	<ul style="list-style-type: none"> • Amyloidosis confirmed • Signed ICF 	PI: Thomas Fehr thomas.fehr@ksgr.ch CRC: Gabriela Manetsch gabriela.manetsch@ksgr.ch

Open clinical trials CTU

Nephrology			
Short title	Complete title	Key Inclusions	Contact
SIDIA	Short-term effects of an SGLT2 Inhibitor on divalent ions in autosomal dominant polycystic kidney disease	<ul style="list-style-type: none"> Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria¹⁴, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan Informed consent as documented by signature 	PI: Lorena Roth lorena.roth@ksgr.ch CRC: Cornelia Fluri cornelia.fluri@ksgr.ch

Open clinical trials CTU

Pneumology			
Short title	Complete title	Key Inclusions	Contact
ASCENT	Asthma Control in Severe Asthma Patients Treated with Tezepelumab: a Prospective, Observational, Real-World Evidence Study	<ul style="list-style-type: none"> • Diagnosis of asthma for at least 52 weeks • Received at least one prescription of medium-dose to high-dose ICS during the 52 weeks prior to enrolment • Documented history of at least 1 asthma exacerbation during the 52 weeks prior to enrolment date 	PI: Tsogyal Latshang tsogyal.latshang@ksgr.ch CRC: Cornelia Fluri cornelia.fluri@ksgr.ch